Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
82,051,282
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
60,143,341
-
Shares change
-
+8,254,898
-
Total reported value, excl. options
-
$1,309,923,497
-
Value change
-
+$204,167,783
-
Put/Call ratio
-
29%
-
Number of buys
-
66
-
Number of sells
-
-59
-
Price
-
$21.78
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q4 2023
156 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value as of Q4 2023.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60,143,341 shares
of 82,051,282 outstanding shares and own 73% of the company stock.
Largest 10 shareholders include FMR LLC (7,625,542 shares), Paradigm Biocapital Advisors LP (4,794,488 shares), VR Adviser, LLC (3,882,623 shares), Deep Track Capital, LP (3,631,728 shares), BlackRock Inc. (3,426,450 shares), VANGUARD GROUP INC (3,000,948 shares), STATE STREET CORP (2,708,383 shares), MAVERICK CAPITAL LTD (2,325,841 shares), ALLIANCEBERNSTEIN L.P. (2,059,464 shares), and COMMODORE CAPITAL LP (1,924,074 shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.